New 2-substituted, 4-amino-thiazolo(4,5-d) pyrimidines, useful as chemokine receptor antagonists, esp. CX3CR1

Details for Australian Patent Application No. 2004278276 (hide)

Owner AstraZeneca AB

Inventors Sohn, Daniel; Zemribo, Ronald; Nordvall, Gunnar; Rein, Tobias

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004278276

PCT Pub. Number WO2005/033115

Priority 0302666-3 07.10.03 SE; 0302667-1 07.10.03 SE

Filing date 5 October 2004

Wipo publication date 14 April 2005

Acceptance publication date 18 October 2007

International Classifications

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

C07D 475/06 (2006.01) Heterocyclic compounds containing pteridine ring systems

C07D 513/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

Event Publications

27 April 2006 PCT application entered the National Phase

  PCT publication WO2005/033115 Priority application(s): WO2005/033115

18 October 2007 Application Accepted

  Published as AU-B-2004278276

14 February 2008 Standard Patent Sealed

29 April 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004278282-Novel calcium channels and uses thereof

2004278264-Plastic bottles